| Predictor | Breast Cancer Screening | Bowel Cancer Screening | Hip Fracture Prevention | CVD Prevention | ||||
|---|---|---|---|---|---|---|---|---|
| % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | |
| Age, y | ||||||||
| 50-54 | 58 (46-68) | 0.4 (0.2-0.7) | 56 (45-66) | 0.4 (0.2-0.7) | 52 (42-63) | 0.7 (0.4-1.2) | 28 (19-39) | 0.5 (0.3-0.9) |
| 55-59 | 71 (60-80) | 0.8 (0.4-1.3) | 70 (59-79) | 0.7 (0.4-1.3) | 64 (53-74) | 1.0 (0.6-1.8) | 48 (37-58) | 1.0 (0.6-1.8) |
| 60-64 | 81 (72-88) | 1.5 (0.9-2.5) | 84 (75-90) | 1.2 (0.7-2.0) | 71 (62-79) | 1.3 (0.7-2.2) | 59 (49-69) | 1.3 (0.8-2.3) |
| 65-70 | 78 (68-86) | 1.0 | 79 (69-87) | 1.0 | 71 (61-81) | 1.0 | 51 (40-62) | 1.0 |
| P valueb | <.0001 | .0006 | .11 | .006 | ||||
| Sex | ||||||||
| Male | 68 (61-74) | 1.0 | 70 (64-76) | 1.0 | 63 (56-69) | 1.0 | 42 (35-49) | 1.0 |
| Female | 78 (71-84) | 1.4 (0.9-2.0) | 78 (70-84) | 1.4 (1.0-2.1) | 68 (61-75) | 1.3(0.9-2.0) | 54 (46-62) | 1.6 (1.1-2.3) |
| P valuec | .12 | .081 | .16 | .022 | ||||
| Educationd | ||||||||
| Lower | 84 (76-90) | 1.0 | 86 (79-92) | 1.0 | 82 (74-89) | 1.0 | 67 (58-76) | 1.0 |
| Higher | 67 (61-73) | 0.4 (0.2-0.6) | 67 (61-73) | 0.4 (0.2-0.5) | 54 (48-60) | 0.4 (0.3-0.7) | 38 (32-45) | 0.4 (0.3-0.5) |
| P valuec | <.0001 | <.0001 | .0001 | <.0001 | ||||
| Past experiencee | ||||||||
| No | – | – | 73 (67-78) | 0.8 (0.5-1.2) | 65 (60-71) | 1.0 (0.5-1.8) | 48 (42-53) | 1.0 (0.6-1.8) |
| Yes | – | – | 73 (64-80) | 1.0 | 62 (47-75) | 1.0 | 47 (33-61) | 1.0 |
| P valuec | – | .3 | .93 | .95 | ||||
VD = cardiovascular disease; OR = odds ratio.
↵a OR calculated from multivariable logistic regression with the proportional odds assumption, across all response levels excluding unknown. OR >1.0 indicates higher estimates of benefit.
↵b df = 3.
↵c df = 1.
↵d Lower = primary or secondary school only. Higher = post-school qualification.
↵e Prior bowel cancer screening, diagnosis of osteoporosis or current medication for osteoporosis, and history of vascular disease. Breast cancer screening—only 5 women had never been screened so not included in the mode.